Observational Study on Vasopressor Levels and 30-Day Survival in Adults with Cardiogenic Shock Receiving VA-ECMO Support

What this Trial Is About

Researchers are studying adults with cardiogenic shock who require venoarterial extracorporeal membrane oxygenation VA-ECMO support to understand how different levels of vasopressor use affect survival. This observational study aims to determine if lower vasopressor exposure reduces the risk of death within 30 days. The goal is to find the best ways to manage blood pressure and ECMO settings to improve patient outcomes. The study will include 534 patients from multiple centers, grouped by their average Vasoactive-Inotropic Score VIS measured from 12 hours after starting ECMO until weaning. One group will have high vasopressor doses VIS >10, and the other will have low doses VIS 10. Researchers will observe these groups without changing their treatment, focusing on natural variations in vasopressor exposure. Participants will have their medical data collected during their care, including vasopressor use, survival rates, time on mechanical ventilation, length of ICU and hospital stay, and any ECMO-related complications. Hemodynamic measurements and lab tests will also be monitored. The primary measure is 30-day all-cause mortality, with follow-up up to six months. The study involves no treatment changes and relies on data from routine care.

Effect of Reduced Vasopressors on Mortality in ECMO-supported Cardiogenic Shock Patients